PHARMACYTE BIOTECH, INC. (PMCB)

0.52 -4.66% (-0.03)

Over 1Y: -46.4%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

0.5 0.75 1 1.25
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '22 — Revenue: 0 Q1 '22 — Net Income: -1M Q2 '22 — Revenue: 0 Q2 '22 — Net Income: -979.7K Q3 '22 — Revenue: 0 Q3 '22 — Net Income: -811.3K Q4 '22 — Revenue: 0 Q4 '22 — Net Income: -1.4M Q1 '23 — Revenue: 0 Q1 '23 — Net Income: -1.5M Q2 '23 — Revenue: 0 Q2 '23 — Net Income: -1.9M Q3 '23 — Revenue: 0 Q3 '23 — Net Income: -764.1K Q4 '23 — Revenue: 0 Q4 '23 — Net Income: -126.3K Q1 '24 — Revenue: 0 Q1 '24 — Net Income: -3.2M Q2 '24 — Revenue: 0 Q2 '24 — Net Income: 2.8M Q3 '24 — Revenue: 0 Q3 '24 — Net Income: -619.5K Q4 '24 — Revenue: 0 Q4 '24 — Net Income: -2.5M Q1 '25 — Revenue: 0 Q1 '25 — Net Income: 23.4M Q2 '25 — Revenue: 0 Q2 '25 — Net Income: -1.5M Q3 '25 — Revenue: 0 Q3 '25 — Net Income: -3M Q4 '25 — Revenue: 0 Q4 '25 — Net Income: 11.7M Q1 '26 — Revenue: 0 Q1 '26 — Net Income: -8.4M Q2 '26 — Revenue: 0 Q2 '26 — Net Income: -7.4M Q3 '26 — Revenue: 0 Q3 '26 — Net Income: 746.9K Q4 '26 — Revenue: 0 Q4 '26 — Net Income: -4.4M -7M 0 7M 14M 21M 28M
Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26
Revenue Free Cash Flow Net Income

Figures as at 2026-04-30, reported in USD. The newest fact in the filings is dated 2026-04-30, 122 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
ROIC -37.5%
Accruals -30.5%
ROA -41.5%
ROCE -14.9%
ROE -58.3%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
SBC / sales —

1 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.8
Current ratio 45.3×
ND/EBITDA —
Cash runway 3.7 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 45.3×
F-score 2.6 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

0.5
EPS Y/Y -155.4%
Shares change +14.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —
Sales/sh Y/Y —

0 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.